Viatris Inc. (VTRS)
| Market Cap | 20.00B +114.5% |
| Revenue (ttm) | 14.56B +1.6% |
| Net Income | -296.50M |
| EPS | -0.26 |
| Shares Out | 1.16B |
| PE Ratio | n/a |
| Forward PE | 6.92 |
| Dividend | $0.48 (2.80%) |
| Ex-Dividend Date | May 22, 2026 |
| Volume | 20,242,489 |
| Open | 17.30 |
| Previous Close | 17.39 |
| Day's Range | 16.65 - 17.53 |
| 52-Week Range | 8.19 - 17.53 |
| Beta | 0.87 |
| Analysts | Buy |
| Price Target | 15.40 (-10.31%) |
| Earnings Date | May 7, 2026 |
About VTRS
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CN... [Read more]
Financial Performance
In 2025, Viatris's revenue was $14.30 billion, a decrease of -2.98% compared to the previous year's $14.74 billion. Losses were -$3.51 billion, 454.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for VTRS stock is "Buy." The 12-month stock price target is $15.4, which is a decrease of -10.31% from the latest price.
News
Viatris price target raised to $20 from $18 at Truist
Truist raised the firm’s price target on Viatris (VTRS) to $20 from $18 and keeps a Buy rating on the shares. The company’s Q1 results featuring a 5% revenue beat
Viatris price target raised to $18 from $17 at JPMorgan
JPMorgan raised the firm’s price target on Viatris (VTRS) to $18 from $17 and keeps a Neutral rating on the shares.
Viatris to Present at the Bank of America Securities 2026 Healthcare Conference
PITTSBURGH, May 7, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the Bank of America Securities 2026 Healthcare Confer...
Viatris beats quarterly estimates on China strength, branded drug sales
Viatris topped analysts' estimates for first-quarter revenue and profit on Thursday, buoyed by strength in its China business and strong demand for branded drugs.
Viatris reports Q1 adjusted EPS 59c, consensus 50c
Reports Q1 revenue $3.52B, consensus $3.36B. “We delivered a strong first quarter, reflecting disciplined execution across our global businesses,” said Scott A. Smith, CEO, Viatris (VTRS). “Our perfor...
Viatris backs FY26 adjusted EPS view $2.23-$2.47, consensus $2.44
Backs FY26 revenue view $14.45B-$14.95B, consensus $14.64B. Backs FY26 adjusted EBITDA view $4.15B-$4.45B.
Viatris Earnings Call Transcript: Q1 2026
Q1 2026 delivered 3% revenue growth and 10% adjusted EBITDA growth, led by strong performance in Greater China and North America. Multiple product launches and regulatory milestones are expected in 2026, with disciplined capital allocation and cost optimization supporting future growth.
Viatris Reports First-Quarter 2026 Financial Results
Delivers Total Revenues of $3.5 Billion, Representing 8% Reported Growth Compared to First Quarter 2025, and U.S. GAAP Net Earnings of $176 Million Total Revenues Were Up 3% Operationally Compared to ...
Viatris Announces Quarterly Dividend
PITTSBURGH, May 5, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on May 4, 2026, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and out...
Viatris CFO Theodora Mistras to depart, Paul Campbell named interim CFO
Viatris (VTRS) announced that Theodora “Doretta” Mistras, CFO, will depart the company for a new professional opportunity. Viatris has named Paul Campbell, currently Chief Accounting Officer and Corpo...
Viatris Announces Chief Financial Officer Transition
Theodora "Doretta" Mistras to Depart; Paul Campbell Named Interim CFO PITTSBURGH, May 4, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Theodora "D...
Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting
PITTSBURGH, May 1, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that six abstracts on its investigational low-dose estrogen combined hormonal contrace...
Viatris to Report First Quarter 2026 Financial Results on May 7, 2026
PITTSBURGH, April 13, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. Compa...
Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
PITTSBURGH, April 10, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that four abstracts will be presented at the American Society of Cataract and Refra...
Viatris price target raised to $17 from $15 at Barclays
Barclays raised the firm’s price target on Viatris (VTRS) to $17 from $15 and keeps an Overweight rating on the shares. The “muted reaction” to Viatris’ investor day is unsurprising
Viatris announces approval for Effexor SR 37.5 mg / 75 mg capsules in Japan
Viatris (VTRS) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has approved Effexor SR 37.5 mg / 75 mg capsules, a serotonin-noradrenaline reuptake inhibitor, for the treatment
Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)
Addresses a Significant Unmet Need in Japan as First and Only Approved Treatment Option for GAD PITTSBURGH, March 23, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, tod...
Viatris Transcript: Investor update
A focused transformation has positioned the company for sustainable growth, targeting 5%-6% revenue and 7%-8% EBITDA growth by 2030, with over $11B in capital for deployment. Key drivers include a robust pipeline, disciplined business development, and operational efficiencies.
Viatris outlines vision for growth through 2030
Viatris (VTRS) will host its Investor Event, where members of the executive leadership team will outline the Company’s strategic vision, key drivers and financial framework expected to deliver sustain...
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030
Growing Base Business Evolving Into More Durable Portfolio of Higher-Margin Generics, Value-Added Medicines and Established Brands Expecting Impactful Near-Term Launches, Including Fast-Acting Meloxic...
Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research
Generic drugmaker Viatris has settled a lawsuit brought by the family of Henrietta Lacks, a Maryland woman whose tissue samples were used without her permission to develop enduring cells for lucrativ...
Unusually active option classes on open March 12th
Unusual total active option classes on open include: Grabagun Digital Holdings Inc. (PEW), Viatris (VTRS), SK Telecom (SKM), Dicks (DKS), Mosaic (MOS), Poet Technologies (POET), United States Brent Oi...
AI Is Sliding and Everything Else Has Run Up. Here Are 6 Stocks That Look Like Buys.
It can seem like a nothing-to-buy market. But there are solid stocks out there.
Viatris price target raised to $20 from $18 at UBS
UBS raised the firm’s price target on Viatris (VTRS) to $20 from $18 and keeps a Buy rating on the shares. Viatris achieved its Q4 cost-saving targets and provided FY26